Retatrutide Side Effects: What Trials Report & How Long They Last
Retatrutide side effects from clinical trials: dose-related GI symptoms, the Phase 3 dysesthesia signal, heart rate, serious events and the GLP-1 thyroid warning.
Retatrutide (LY3437943) is an investigational triple agonist, so its safety picture comes entirely from clinical trials rather than years of real-world prescription use. This guide reports what those trials actually documented, with sources, and is careful to separate peer-reviewed Phase 2 data from the Phase 3 figures that have only been announced as topline results.
Retatrutide is not an approved medication. It remains investigational and is being studied in clinical trials. Nothing here is medical advice. If you are in a trial and experience concerning symptoms, contact your study team.
The most common side effects: gastrointestinal
Like other incretin-based drugs, retatrutide's most common side effects are gastrointestinal, dose-related, and concentrated during dose escalation. In the Phase 2 obesity trial (NEJM, 2023), these were mostly mild to moderate, and the trial deliberately started at a low dose to limit them.
A 2025 systematic review and meta-analysis pooling the Phase 2 trials quantified how much more likely each GI effect was versus placebo at the higher doses — a more defensible way to present the data than single-trial raw percentages:
| Side effect | Higher-dose risk vs placebo |
|---|---|
| Nausea | About 4× more likely |
| Vomiting | About 9× more likely |
| Diarrhea | About 2× more likely |
| Constipation | About 4× more likely |
The practical pattern, familiar from the wider GLP-1 class, is that these symptoms flare when the dose steps up and settle as the body adjusts. That's the entire reason trials titrate slowly — see retatrutide dosing in clinical trials.
How long do they last?
Because the GI effects are escalation-linked, they tend to be worst in the days to weeks after a dose increase and to ease once the dose holds steady. The trials don't define a single fixed duration — it depends on the individual and on how fast the dose is raised. The takeaway is that the symptoms are generally transient and dose-driven rather than permanent, which is why a slower titration is the standard lever for managing them.
The Phase 3 skin-sensation signal (dysesthesia)
One side effect that became prominent only in Phase 3 is dysesthesia — an altered skin sensation such as tingling or discomfort. According to Lilly's TRIUMPH-4 topline announcement (December 2025), dysesthesia was reported in about 8.8% of participants at 9 mg and 20.9% at 12 mg, versus 0.7% on placebo — described as generally mild and infrequently leading to discontinuation.
This is worth flagging precisely because it was not a headline finding in the earlier Phase 2 trial; it's a signal that larger, longer studies surfaced. It's also a good illustration of why investigational drugs need full Phase 3 review before their complete side-effect profile is known. Note this figure comes from a topline press release, not yet a peer-reviewed publication.
Heart rate
Like the GLP-1 class generally, retatrutide was associated with dose-dependent increases in heart rate in the Phase 2 trial. The reported pattern was that the increase peaked around 24 weeks and then declined. This is a known class-level effect worth monitoring, but in the trial it was modest and followed a rise-then-decline course rather than climbing indefinitely.
Serious adverse events
Serious adverse events in the Phase 2 trial were uncommon and broadly comparable to placebo — on the order of 4% in the placebo group and ranging from roughly 0–6% across the retatrutide dose groups. One case of acute pancreatitis was reported among the serious events. In the TRIUMPH-4 Phase 3 topline data, serious adverse events were again reported at around 4% in both the retatrutide and placebo arms.
Discontinuation tells a similar story scaled by dose. In Phase 2, adverse events led 6–16% of retatrutide participants to stop the drug, versus none on placebo — the higher end corresponding to higher doses.
The GLP-1 class thyroid warning
Because retatrutide includes GLP-1-receptor activity, the class-level thyroid concern applies as a consideration. GLP-1 receptor agonists carry a warning rooted in rodent studies that showed thyroid C-cell tumors, and the class is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Importantly, no thyroid C-cell or MTC signal specific to retatrutide has been reported in its published trial data to date. The honest framing is that this is a class-based caution carried over because of retatrutide's GLP-1 component, not a confirmed retatrutide finding.
A note on unregulated "research" product
Everything above describes the clinical-trial drug under controlled conditions. Product sold online as "retatrutide" is not verified to match the trial molecule in identity, purity, dose, or sterility — which adds risks that have nothing to do with the drug's intrinsic pharmacology. The approved-medicine versus research-grade distinction matters a great deal for safety.
The bottom line
Retatrutide's trial side-effect profile looks like a stronger-dose member of the incretin family: mostly transient, dose-related GI symptoms, a manageable heart-rate effect, and serious-event rates close to placebo — plus a Phase 3 skin-sensation (dysesthesia) signal that deserves attention as the data matures. The GLP-1 class thyroid caution applies on paper, with no retatrutide-specific signal reported. But this is investigational data: long-term safety is not yet established, and that uncertainty is the whole point of the ongoing trials.
For efficacy context, see retatrutide results; for the mechanism behind these effects, see how retatrutide works.
FAQ
What are the most common retatrutide side effects?
Gastrointestinal symptoms — nausea, vomiting, diarrhea and constipation. They are dose-related, hit hardest during dose escalation, and are usually mild to moderate. In the Phase 2 trial, vomiting was roughly nine times more likely and nausea about four times more likely than on placebo at the higher doses.
How long do retatrutide side effects last?
The common GI effects are tied to dose escalation and tend to ease once the dose stabilizes. Trials use gradual dose increases specifically to limit them. Exact duration varies by person and how quickly the dose is raised.
What is the dysesthesia side effect of retatrutide?
Dysesthesia is an altered skin sensation (such as tingling). It emerged as a notable signal in the Phase 3 TRIUMPH-4 topline data, reported in about 20.9% of participants at the 12 mg dose versus 0.7% on placebo, described as generally mild and rarely causing people to stop. It was not a prominent finding in the earlier Phase 2 trial.
Does retatrutide carry a thyroid cancer warning?
Retatrutide includes GLP-1 activity, and the GLP-1 drug class carries a warning based on thyroid C-cell tumors seen in rodents, with a contraindication for people with a personal or family history of medullary thyroid carcinoma or MEN 2. No thyroid signal specific to retatrutide has been reported in its published trial data so far.
References
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023.
Eli Lilly and Company. TRIUMPH-4 Phase 3 topline results announcement. December 2025.
Novo Nordisk / U.S. FDA. Wegovy (semaglutide) prescribing information — GLP-1 class thyroid C-cell warning. DailyMed.